VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience

Archives of Gerontology and Geriatrics
Kazuyoshi IshiiShosaku Nomura

Abstract

CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) plus rituximab is a standard chemotherapy used to treat patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL). However, among elderly patients, this regimen has not been completely satisfactory in its efficacy and safety. We report our clinical experience in 8 collaborative institutions to determine if the VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone, and bleomycin) combination therapy plus rituximab was effective and safe to treat elderly patients with aggressive B-NHL. Between September 2004 and December 2007, 23 previously untreated patients, median age 73 years, 50.0% classified as high-intermediate/high-risk on the standard International Prognostic Index (IPI) entered this trial. Complete remission rate was 90.5%, with a 100% overall response rate (RR) at the end of induction therapy; overall survival (OS) rate at 3 years was 76.4% (median follow-up 744 days), with an 82.6% 3-year progression-free survival (PFS) rate (median follow-up 744 days). The most common grade 3/4 toxicities were hematologic, including neutropenia in 75.0% of the patients despite prophylactic administration of granulocyte colony-stimulating fac...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J K DoorduijnP Sonneveld
Sep 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanRichard I Fisher
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithAntonio C Wolff
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Nov 3, 2006·Archives of Gerontology and Geriatrics·László VáróczyArpád Illés
Nov 9, 2007·Leukemia & Lymphoma·Mariapaola FinaPier Luigi Zinzani
Dec 13, 2007·International Journal of Health Services : Planning, Administration, Evaluation·Ryuichi Komatsu, Takashi Sawada
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel O PerskyUNKNOWN Southwest Oncology Group
Jun 25, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D EnnishiK Hatake

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.